**QUOTIENT SCIENCES COMPANY ANNOUNCEMENT**

**FOR IMMEDIATE USE**

**Oxilio and Quotient Sciences Announce Regulatory Approval   
for Oxilio’s OXL001 Development Program**

**NOTTINGHAM, UK; September 29th, 2022** – Oxilio, a pioneering drug development company repurposing existing drugs to address unmet needs in cancer treatment, and Quotient Sciences, a drug development and manufacturing accelerator, today announced an update on the development of Oxilio’s OXL001 product.

Oxilio is pleased to announce that it has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) and Research Ethics Committee (REC) for its first Clinical Trial Application (CTA) with OXL001. Following initial formulation development by Oxilio in collaboration with its partner company, TRx Biosciences, Quotient Sciences’ integrated Translational Pharmaceutics® platform has been used to carry out the technical transfer and scale-up activities associated with this program and will continue to be used to support clinical trial material manufacturing and the investigation of the pharmacokinetics and safety of OXL001 in healthy volunteers.

Mark Egerton, Ph.D., CEO of Quotient Sciences, said: “We are delighted to be able to continue to assist Oxilio with their OXL001 program. By leveraging our unique, integrated Translational Pharmaceutics platform, Oxilio will have the flexibility to adjust doses based on emerging clinical data within their study, enabling us to improve their likelihood of success, reduce their development time, and ultimately get new medicines to patients faster.”

Dr. Simon Yaxley, Director of Oxilio, added: “Utilizing Quotient Sciences’ Translational Pharmaceutics platform has enabled us to successfully achieve this important milestone of receiving regulatory approval to undertake our first Phase 1 clinical trial with OXL001. We look forward to commencing this study within the next few weeks.

END

**About Quotient Sciences**

Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients. Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, and molecules need to become cures, fast. Because humanity needs solutions, fast. For more information, please visit [quotientsciences.com](https://bit.ly/3Bz1J7l).

**Quotient Sciences Company Contact**

Kimberly Burrell

Executive Director of Global Marketing

(509) 910-1551

[Kimberly.Burrell@QuotientSciences.com](mailto:Kimberly.Burrell@QuotientSciences.com)

**About Oxilio**

Oxilio is a pioneering pharmaceutical drug development company improving cancer treatment through rapid, cost-effective drug development. Our mission is to identify, repurpose, and commercialize existing drugs to address unmet needs in cancer therapy. We find new uses for old drugs, a proven approach that involves less risk, time, and cost to bring a drug to the marketplace. Through repurposing, reformulation, and gold-standard modeling and simulations, we are fast-tracking disruptive drug development at speed and at low cost.

**Oxilio Company Contact**

[info@oxilio.co.uk](mailto:info@oxilio.co.uk)